Compare Charles River Laboratories Intl. Inc (CRL) vs SkyWest Inc (SKYW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs SkyWest Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $229.81 (market cap $11.14B), while SkyWest Inc trades at $98.89 (market cap $3.85B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 2.9× SkyWest Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, SkyWest Inc nearer its low. Which is the better fit depends on your goals.
| CRL | SKYW | |
|---|---|---|
Market Cap | $11.14B | $3.85B |
Sector | Health | Technology |
52-Week High | $233.60 | $123.72 |
52-Week Low | $145.57 | $78.40 |
Enterprise Value | $14.00B | $5.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
SkyWest (SKYW) trades at $97.78, down 1.95% on the day, with a bullish technical signal from moving averages and a neutral RSI. The stock shows strong fundamentals with a P/E of 9.32 and net income margin of 10.42%, supported by recent earnings beats. Analyst consensus is bullish with a $109.33 price target. Recent news includes a key executive appointment and attention to fuel cost pressures in the airline industry.
The outlook for SKYW is positive given its attractive valuation and profitability, but risks include rising fuel expenses and industry volatility. With no sell ratings and 56% buy consensus, the stock presents a compelling opportunity for upside, though investors should monitor cost management and quarterly results closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
